Teladoc Health’s $1 Billion Loss in 2024: A Telehealth Giant Faces Turbulence

In partnership with

Teladoc Health, a leader in telemedicine, ended 2024 with a staggering $1 billion net loss, sending shockwaves through the industry and raising concerns among investors. The financial setback, revealed in the company’s full-year earnings on February 26, 2025, marks a sharp decline from the $220.4 million loss in 2023. Once hailed as the future of healthcare during the pandemic boom, Teladoc now faces significant challenges. So, what went wrong, and what does this mean for the company’s future?

Your Breakfast Is Holding You Back

Coffee alone isn’t breakfast.

For lasting energy, peak performance, and real health benefits, your body needs more than just empty calories. That’s where Huel Black Edition steps in. Packed with 40g of protein and 27 essential vitamins, it’s the ultimate high-protein meal, ready in just 30 seconds.

Start fueling your day the right way. Use code BEHUEL15 for 15% off your first order, plus a FREE t-shirt and shaker.

Upgrade Your Breakfast Today

A Tale of Two Segments

The primary cause of Teladoc’s troubles lies in its direct-to-consumer mental health platform, BetterHelp. Once a major revenue driver, BetterHelp saw its performance take a nosedive in 2024. Revenue dropped by 8% to $1.04 billion, with a 10% decline in the fourth quarter alone, bringing in $249.8 million. Worse still, the platform’s paying user base shrank by 11% compared to the previous year, indicating that BetterHelp is losing its competitive edge. The company also took a massive $790 million goodwill impairment charge in the second quarter, signaling a significant reassessment of BetterHelp’s future prospects. While this write-down contributed heavily to the year’s loss, it also highlights deep underlying issues.

On a more positive note, Teladoc’s Integrated Care segment, which focuses on business-to-business services for health plans, employers, and health systems, showed modest growth. Revenue for this division rose 4% to $1.5 billion for the year, with a 2% increase in the fourth quarter, totaling $390.7 million. Membership grew by 8%, and chronic care programs like diabetes management saw 9% growth. While promising, these gains were insufficient to offset the losses from BetterHelp.

The Financial Breakdown

Overall, Teladoc's 2024 revenue fell slightly by 1% to $2.57 billion, compared to $2.6 billion in 2023. The fourth-quarter revenue dropped 3% to $640.5 million, missing Wall Street's expectations and leading to a 16% decline in stock price during after-hours trading. The company’s net loss of $1 billion, or $5.87 per share, starkly contrasts with the $220.4 million loss from the previous year. Adjusted EBITDA, a key profitability metric, fell 5% to $310.7 million for the year, with a 35% drop in Q4 to $74.8 million. Operating cash flow also decreased, falling to $293.7 million from $350 million in 2023.

Despite holding $1.3 billion in cash at the end of 2024, the company’s financial outlook remains troubling. Teladoc’s stock price has plummeted by 61.6% in 2024, and the company is now trading at a fraction of its peak value during the pandemic.

What’s Behind the Decline?

The issues with BetterHelp are multifaceted. Rising customer acquisition costs—particularly during the lead-up to the 2024 U.S. presidential election—have made it more expensive to attract new users. Meanwhile, the mental health market has become increasingly competitive, with rivals like Talkspace gaining ground. As a result, BetterHelp’s user base has declined, and its adjusted EBITDA dropped 43%, falling to $77.8 million. This is a sharp contrast to its explosive growth in 2022, when revenue soared by 41%.

In addition to BetterHelp’s struggles, Teladoc is grappling with a post-pandemic environment where the telehealth boom has begun to plateau. The rapid growth seen in 2020 and 2021 has slowed, and profitability remains elusive. The company’s $18.5 billion acquisition of Livongo in 2020, which was meant to strengthen its chronic care offerings, has yet to provide the expected synergies, as evidenced by a $13.4 billion impairment in 2022.

Leadership changes have also contributed to the company’s instability. CEO Jason Gorevic stepped down in April 2024 following disappointing earnings, and Chuck Divita, a former insurance executive, took over in June. Divita now faces the daunting task of leading Teladoc through its current financial challenges.

A Path Forward?

Despite these setbacks, Teladoc is not giving up. In his February 2025 earnings call, Divita expressed optimism, describing 2024 as a "solid finish" despite the troubling numbers. The company is focused on cost-cutting efforts, which have already exceeded expectations. It is also looking to expand its presence in chronic care and international markets. Teladoc recently acquired Catapult Health, a virtual preventative care provider, for $65 million, hoping to integrate it into its ecosystem and attract new users, especially for conditions like diabetes and hypertension.

For BetterHelp, Teladoc is exploring new strategies, including international expansion, a new pricing model, and discussions with health plans to integrate insurance coverage. Divita is optimistic about leveraging BetterHelp’s brand to increase utilization, but he acknowledges that the platform’s stability remains uncertain. "We have not yet reached the level we’re striving for," he said.

Looking to 2025, Teladoc has projected revenue between $2.47 billion and $2.58 billion, with a net loss per share ranging from $1.10 to $0.50. The cautious outlook reflects the challenges the company faces moving forward.

Why This Matters

Teladoc’s struggles offer valuable insights into the evolution of telehealth. Once a darling of the tech and healthcare worlds, the company now finds itself at a crossroads. Can it adapt to a more mature and competitive market, or will it become a casualty of its own rapid expansion? For patients, a faltering Teladoc might mean fewer options for virtual care or potentially higher costs if the company cuts back too much. For the broader healthcare industry, Teladoc’s story serves as a cautionary tale about the risks of overexpansion and the challenges of sustaining growth in an increasingly crowded market.

As of March 3, 2025, Teladoc remains at a critical juncture. Divita’s efforts to turn the company around show some promise, but with losses mounting and stock prices falling, the pressure is on. Whether Teladoc can overcome these hurdles and reclaim its former success remains to be seen. The billion-dollar question is whether it can make a successful comeback or continue its downward trajectory.